Maravai LifeSciences Holdings, Inc.

NASDAQ:MRVI

Biotechnology

Healthcare
$7.38 -2.78%

-$0.15 today

Market cap
$2.10B
Beta
0.71
P/E (TTM)
-7.1
EPS (TTM)
-$0.71
52W Low $1.99High $5.32

Volume 1.41M

Average 2.42M

MRVI Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Maravai LifeSciences Holdings, Inc.NASDAQ: MRVI

Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026

Selling, general & admin declines year over year

Q2 FY2026 selling, general & admin of $32.07M fell 16.9% year over year, behind the -3.6% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 17.3% from the prior quarter. Over 3 fiscal years it compounded at +9.9% a year.

Context

  • Selling, general & admin amounted to 92.3% of revenue in FY2025, up 29.9 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 7 analysts of $100.44M (-41.4%) for the fiscal year ending Dec 2026, a slowdown from the +6.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$32.07M+17.3% QoQ
Last fiscal yearDec 2025
$171.47M+6.0% YoY
LTMJun 2026
$152.74M-3.6% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-16.9%-73.9%-57.0 pp
1 year+6.0%-41.4%-47.4 pp
3-year CAGR+9.9%-12.9%-22.8 pp
5-year CAGR-5.6%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
171.47M USD
Year-over-year change
+6.0%
4-year CAGR
+14.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How MRVI compares with its peers on the latest reported figures

  • MRVI's LTM Jun 2026 selling, general & admin of $152.74M is the 6th highest of the 9 companies compared; the peer median is $272.92M.
  • Its year-over-year change of -3.6% is the 7th highest of 9, against a peer median of +2.4%.
  • Selling, general & admin amounts to 73.2% of revenue for MRVI, versus a peer median of 43.6%.
MRVI Competitors Peer median
Selling, General & Admin for MRVI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$847.8M +3.3%-0.3%32.7%
TECHBio-Techne CorporationLTM Sep 2026$469.88M +14.0%+8.7%38.3%
NEOGNeogen CorporationLTM Aug 2026$406.6M -0.9%+6.3%46.0%
RGENRepligen CorporationLTM Jun 2026$289.52M +3.9%+10.4%36.9%
AZTAAzenta, Inc.LTM Sep 2026$256.31M +1.6%-2.9%41.2%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$152.74M -3.6%+9.9%73.2%
PACBPacific Biosciences of California, Inc.LTM Mar 2026$132.48M -17.6%-4.2%82.8%
LABStandard BioTools Inc.LTM Mar 2026$97.69M -22.9%+2.4%113.3%
BLFSBioLife Solutions, Inc.LTM Mar 2026$56.01M +20.2%+7.2%56.1%
Peer median (excluding MRVI) $272.92M+2.4%+4.4%43.6%

Competitors are the stored peer set for MRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue799.24M883M288.95M259.19M185.74M
Cost of Revenue140.56M168.96M148.74M150.88M152.35M
Gross Profit658.68M714.04M140.2M108.31M33.39M
Gross Margin82.4%80.9%48.5%41.8%18.0%
Research & Development15.22M18.37M17.28M19.22M23.33M
Selling, General & Admin100.06M129.26M151.39M161.77M171.47M
Operating Expenses104.03M139.83M171.85M343.93M40.13M
Depreciation & Amortization24.75M38.1M48.78M56.87M60.47M
EBITDA585.78M609.99M712.41M(156.92M)(147.51M)
EBITDA Margin73.3%69.1%246.6%-60.5%-79.4%
Operating Income554.65M574.22M(31.65M)(235.62M)(6.74M)
Operating Margin69.4%65.0%-11.0%-90.9%-3.6%
Interest Income02.34M27.73M27.4M23.95M
Interest Expense30.26M20.41M45.89M47.7M26.99M
Other Income / Expenses(23.88M)(22.74M)649.38M(25.87M)(228.24M)
Income Before Tax530.77M551.47M617.74M(261.48M)(234.97M)
Pre-Tax Margin66.4%62.5%213.8%-100.9%-126.5%
Income Tax Expense61.52M60.81M756.11M(1.86M)(4.21M)
Net Income182.04M220.21M(119.03M)(144.85M)(130.77M)
Net Margin22.8%24.9%-41.2%-55.9%-70.4%
EPS (Basic)1.591.67(0.90)(1.05)(0.91)
EPS (Diluted)1.561.67(0.90)(1.05)(0.91)
Weighted Avg Shares114.79M131.54M131.92M137.91M145.07M
Weighted Avg Shares (Diluted)121.97M131.7M131.92M137.91M145.07M

Maravai LifeSciences Holdings, Inc.

NASDAQ:MRVI

Intrinsic Alpha fair value

Locked

Current Price

$7.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.